Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4):394-401

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4):394-401

LATEST ADVANCES IN RADIOPHARMACOLOGY AND RADIOPHARMACY 2009 

 REVIEWS

Towards a harmonized radiopharmaceuticalregulatory framework in Europe?

Decristoforo A. 1,2, Peñuelas I. 2,3

1 Clinical Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria;
2 Radiopharmacy Committee of the European Association of Nuclear Medicine, Vienna, Austria;
3 Radiopharmacy Unit, Department of Nuclear Medicine, University of Navarra Hospital, Pamplona, Spain

Despite European unification regarding a common legal framework for many aspects of pharmaceutical production including industrial manufacture of pharmaceuticals, the practice of pharmacy in general, and of radiopharmacy in particular, differs substantially and are mainly regulated at the national level. Herein the authors discuss major European documents relevant for radiopharmacy practice in Europe and recent developments on the national level especially regarding the small-scale preparation of radiopharmaceuticals (RP). Issues related to marketing authorization (and exemptions from it), standards of preparation, quality requirements, regulations of clinical trials and education will be outlined. Standards for the industrial preparation of pharmaceuticals are defined in “Good Manufacturing Practice” (GMP), not taking into account specific requirements for the small scale, extemporaneous preparation of RP. The European Association of Nuclear Medicine EANM has published several documents based on GMP and called "Good Radiopharmaceutical Practice" (cGRPP) to specifically address this in an attempt to harmonize RP preparation across Europe. Clinical trials have been hampered by the introduction of directive 2001/20/EC again aimed at the marketing track of industrial production and currently a number of activities are ongoing to counterbalance this problem in radiopharmaceutical research. Additionally, the role of the European Pharmacopoeia in regulating quality requirements and the need for specific education and training in the small scale radiopharmaceutical preparation are also discussed.

language: English


FULL TEXT  REPRINTS

top of page